- Home
- TOP vs MAIA Comparison
TOP vs MAIA Comparison
Compare TOP & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOP | MAIA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 44.9M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TOP | MAIA |
|---|---|---|
| Price | $1.05 | $1.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.3K | ★ 945.8K |
| Earning Date | 01-26-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,329,256.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $0.87 |
| 52 Week High | $3.33 | $2.74 |
Technical Indicators
Market Signals| Indicator | TOP | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 50.66 |
| Support Level | $1.07 | $1.13 |
| Resistance Level | $1.17 | $1.75 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 38.13 | 25.00 |
Price Performance
Historical ComparisonAbout TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.